Drugs Made In America Acquisition II Corp. (DMIIU) — SEC Filings
Drugs Made In America Acquisition II Corp. (DMIIU) — 7 SEC filings. Latest: 10-Q (Nov 18, 2025). Sentiment: bearish. Includes 3 S-1/A, 2 8-K, 1 10-Q. Overall se
View Drugs Made In America Acquisition II Corp. on SEC EDGAR
Overview
Drugs Made In America Acquisition II Corp. (DMIIU) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 18, 2025: Drugs Made In America Acquisition II Corp. (DMIIU), a blank check company, reported a net loss of $46,158 for the three months ended September 30, 2025, and a net loss of $143,558 for the nine months ended September 30, 2025. This compares to a net loss of $41,684 for the period from inception (Augu
Sentiment Summary
Across 7 filings, the sentiment breakdown is: 3 bearish, 3 neutral, 1 mixed. The dominant filing sentiment for Drugs Made In America Acquisition II Corp. is bearish.
Filing Type Overview
Drugs Made In America Acquisition II Corp. (DMIIU) has filed 1 10-Q, 2 8-K, 3 S-1/A, 1 S-1 with the SEC between Jul 2025 to Nov 2025.
Recent SEC Filings (7)
| Date | Form | Description | Risk |
|---|---|---|---|
| Nov 18, 2025 | 10-Q | DMIIU Raises $500M in IPO, Eyes Pharma Target Amidst Growing Deficit | high |
| Oct 2, 2025 | 8-K | Drugs Made In America Acquisition II Corp. Files 8-K | low |
| Sep 29, 2025 | 8-K | Drugs Made In America Acquisition II Corp. Files 8-K | medium |
| Sep 16, 2025 | S-1/A | DMIIU Files S-1/A for $500M SPAC IPO Targeting Pharma | high |
| Sep 15, 2025 | S-1/A | DMIIU Launches $500M SPAC IPO Targeting Pharma Sector | high |
| Sep 5, 2025 | S-1/A | Drugs Made In America II Files S-1/A for $500M Pharma SPAC IPO | high |
| Jul 21, 2025 | S-1 | DMIIU Files S-1 for SPAC IPO, Eyes 'Made In America' Drug Sector | high |
Risk Profile
Risk Assessment: Of DMIIU's 7 recent filings, 5 were flagged as high-risk, 1 as medium-risk, and 1 as low-risk. The overall risk profile suggests elevated risk that warrants close monitoring.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | $ (143,558) |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $315,087 |
| Operating Margin | N/A |
| Total Assets | $501,005,711 |
| Total Debt | $18,177,345 |
Key Executives
- Lynn Stockwell
- Mitchell S. Nussbaum, Esq.
- Douglas S. Ellenoff, Esq.
- G. Alex Weniger-Araujo, Esq.
- Stuart Neuhauser, Esq.
- Anthony Ain, Esq.
Industry Context
Drugs Made In America Acquisition II Corp. operates within the Special Purpose Acquisition Company (SPAC) sector, which facilitates the public listing of private companies. The broader pharmaceutical and biotechnology industries, the intended focus for DMIIU's business combination, are characterized by high R&D costs, stringent regulatory oversight (FDA), patent cliffs, and significant M&A activity driven by the need for pipeline expansion and innovation.
Top Tags
SPAC (5) · Blank Check Company (5) · IPO (5) · Pharmaceutical Industry (4) · Dilution Risk (3) · Nasdaq Listing (3) · Conflicts of Interest (2) · Trust Account (1) · Deferred Underwriting Fee (1) · Accumulated Deficit (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| IPO Proceeds | $500.0M | Raised from 50,000,000 units at $10.00 each on September 26, 2025. |
| Private Placement Proceeds | $12.0M | From 1,200,000 units sold to Sponsor and Cantor Fitzgerald & Co. |
| Trust Account Balance | $500.1M | Cash and investments held as of September 30, 2025, for future Business Combination. |
| Deferred Underwriting Fee | $17.5M | Significant liability payable upon Business Combination completion. |
| Accumulated Deficit | $17.28M | Increased from $151,719 at December 31, 2024, reflecting operational costs. |
| Net Loss (9 months) | $143,558 | For the nine months ended September 30, 2025, indicating ongoing operational expenses. |
| Interest Income | $109,355 | Earned on cash and investments in Trust Account for the nine months ended September 30, 2025. |
| Ordinary Shares Outstanding | 65,575,000 | As of November 18, 2025, inclusive of shares in outstanding units. |
| Combination Period | 24 months | Deadline from IPO closing (September 26, 2025) to complete a Business Combination. |
| Fair Market Value Threshold | 80% | Minimum fair market value of target business relative to net assets in Trust Account. |
| Commission File Number | 001-42863 | Identifies the company's filing history with the SEC. |
| Business Phone | 954-870-3099 | Contact number for the company's principal executive offices. |
| SEC File Number | 001-42863 | Identifies the company's filing with the SEC. |
| Film Number | 251357469 | Internal SEC processing number for the filing. |
| Public offering price | $500,000,000 | Total proceeds expected from the IPO of 50,000,000 units at $10.00 each |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Drugs Made In America Acquisition II Corp. (DMIIU)?
Drugs Made In America Acquisition II Corp. has 7 recent SEC filings from Jul 2025 to Nov 2025, including 3 S-1/A, 2 8-K, 1 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of DMIIU filings?
Across 7 filings, the sentiment breakdown is: 3 bearish, 3 neutral, 1 mixed. The dominant sentiment is bearish.
Where can I find Drugs Made In America Acquisition II Corp. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Drugs Made In America Acquisition II Corp. (DMIIU) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Drugs Made In America Acquisition II Corp.?
Key financial highlights from Drugs Made In America Acquisition II Corp.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for DMIIU?
The investment thesis for DMIIU includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Drugs Made In America Acquisition II Corp.?
Key executives identified across Drugs Made In America Acquisition II Corp.'s filings include Lynn Stockwell, Mitchell S. Nussbaum, Esq., Douglas S. Ellenoff, Esq., G. Alex Weniger-Araujo, Esq., Stuart Neuhauser, Esq. and 1 others.
What are the main risk factors for Drugs Made In America Acquisition II Corp. stock?
Of DMIIU's 7 assessed filings, 5 were flagged high-risk, 1 medium-risk, and 1 low-risk.
What are recent predictions and forward guidance from Drugs Made In America Acquisition II Corp.?
Forward guidance and predictions for Drugs Made In America Acquisition II Corp. are extracted from SEC filings as they are enriched.